All In Biotech

Free tool

FAERS Monitor: Halog

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017556 or its brand name (Halog, Halcinonide). Reports on generic versions are filed under their own applications.

Reports

194

Serious

59

30% of reports

Hospitalization

31

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective23
  • psoriasis19
  • rash16
  • pain13
  • pruritus13
  • arthralgia12
  • diarrhoea10
  • headache10
  • nausea10
  • fatigue9
  • off label use9
  • condition aggravated7
  • depression7
  • weight decreased7
  • dyspnoea6

Reports by year received

View as table
YearReports
20071
20092
20103
20112
20127
20138
20146
201515
201618
201733
201817
201913
202015
202115
202215
202313
20244
20252
20265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,965 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
psoriasisSignal1915.810.3250
rashSignal164.02.533
pruritusSignal133.72.223
depressionSignal73.31.69
arthralgiaSignal123.11.816
weight decreasedSignal72.71.36
condition aggravatedSignal72.51.25
painSignal132.31.48
drug ineffective231.91.39
headache101.70.92
diarrhoea101.70.92
nausea101.40.71
fatigue91.30.70
dyspnoea61.10.50
off label use91.10.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.